1 / 9

Bordetella (pertussis) (whooping cough) bacterial respiratory childhood infections

Bordetella (pertussis) (whooping cough) bacterial respiratory childhood infections. B . Pertussis B . parapertussis. B .pertussis. Small gram-negative bacilli Most fastidious Culture media containing charcoal bordet-Gengou medium Charcoal blood agar Strict aerobe Slow growth (3 days)

christmas
Télécharger la présentation

Bordetella (pertussis) (whooping cough) bacterial respiratory childhood infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bordetella(pertussis)(whooping cough) bacterial respiratory childhood infections B . Pertussis B . parapertussis

  2. B .pertussis • Small gram-negative bacilli • Most fastidious • Culture media containing charcoal • bordet-Gengou medium • Charcoal blood agar • Strict aerobe • Slow growth (3 days) • 3 major agglutinogens ( attachment ) • (1, 2 and 3) • detected by specific antiserum • Role in immunity • Three serotypes • Type 1,2 • Type1,3 • Type 1,2,3

  3. pathogenesis • Non invasive infection of respiratory mucosa • Ciliated epithelium of bronchi , trachea • Human is the only natural host • IP : 1 – 2 weeks • Tracheal cytotoxin ( TC ) • Pertussis toxin (PT) • Lymphocytosis • Filamentous haemagglutnin (FHA)

  4. clinical • Catarrhal phase ( preventable )-most infectious • Paroxysmal phase ( sever cough) • Convalescent phase • Atypical cases • Complications • Bronchopneumonia • Secondary infection • Lung collapse • Anoxia , convulsions

  5. EPIDEMIOLOGY • SOURSE • Patients ( droplets ) – child or adults • Atypical cases • Cmunicable • Epidemics • Antibiotics reduce transmission • Incidence and mortality • All ages • Cause of death ( < 2 years , infants )

  6. Immunity • One attack confers long lasting immunity • (herd immunity) • Infection with different serotype • Passive protection from mother is incomplete • 3 – injections of vaccine – effective active immunity

  7. Diagnosis • Clinical • lymphocytosis • Laboratory • Nasopharynx (postnasal swab ) • Pernasal swab • Selective media • Slid agglutinations ( antiserum)

  8. Treatment • No effect in well established infection • Erythromycin • Reduce severity if given before paroxysmal phase • For 14- days • Reduces transmission • Prophylaxis of contacts

  9. Control • Vaccination is safe - > 90% effective • Whole bacterial cell ( killed) – deep IM inj. • Contain 3 – agglutinogens • 3 – doses • SE : neurological sequelae , crying , fever • Acellular pertussis vaccine • PT , FHA + agglutinogens

More Related